The company's primary focus is on rare endocrine disorders, specifically endogenous Cushing's syndrome and acromegaly. Strongbridge Biopharma aims to address the high unmet need for innovative treatment options for these rare diseases. They plan to use a small, focused sales force to market their products in key global markets. Additionally, the company is actively seeking to identify and acquire complementary products or product candidates to expand their rare disease franchise. Strongbridge Biopharma's product portfolio includes COR-003, a cortisol inhibitor for endogenous Cushing's syndrome, COR-005, a novel somatostatin analog for acromegaly, and BP-2002, a gene modified probiotic for diabetes treatment.